The López-Belmonte family increase their interest in ROVI to 63.1%

The majority shareholders of Laboratorios Farmacéuticos Rovi, S.A. increase their interest in ROVI to 35,383,462 shares


The López-Belmonte family, the principal shareholders of Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”), have increased their interest in the company’s share capital to 63.107% through their investment vehicle Norbel Inversiones, S.L., which has thus become the direct holder of 35,383,462 of ROVI’s shares.

Juan López-Belmonte Encina said: This increase in the interest held by Norbel Inversiones, S.L. in ROVI’s share capital reflects the López-Belmonte family’s clear bet on the company and our confidence in ROVI’s business model and its future prospects”.

No votes yet
 
Related
On his visit to the plant, which is ready to start production as soon as the authorisation from the Spanish Agency of Medicines and...
4 min
24/10/2022
Glicopepton Biotech founded to produce compounds of high technological value   · ROVI, Càrniques Celrà and Grupo Costa announce...
3 min
04/10/2022
ROVI tops the Sustainalytics sustainability ranking for the pharmaceutical subindustry worldwide Laboratorios Farmacéuticos ROVI...
2 min
01/08/2022